欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (10): 1153-1158.doi: 10.12092/j.issn.1009-2501.2018.10.011

• 药物治疗学 • 上一篇    下一篇

法舒地尔联合瑞舒伐他汀治疗血管性痴呆对认知功能、C-反应蛋白及氧化应激的影响

陈娟燕1,2,宋水江1,徐冬娟2,徐 琼2,李鸿飞2   

  1. 1浙江大学医学院附属第二医院神经内科,杭州 310009,浙江; 2东阳市人民医院神经内科,东阳 322100,浙江
  • 收稿日期:2018-04-25 修回日期:2018-06-24 出版日期:2018-10-26 发布日期:2018-10-25
  • 通讯作者: 宋水江,男,博士,教授,研究方向:脑血管疾病。 E-Mail:chenjuanyan@tom.com
  • 作者简介:陈娟燕,女,本科,研究方向:神经内科。 Tel:0571-87783777 E-mail:371509645@qq.com

Effects of fasudil combined with rosuvastatin in the treatment of vascular dementia on patients' cognitive function, C-reactive protein and oxidative stress

CHEN Juanyan 1,2, SONG Shuijiang 1, XU Dongjuan 2, XU Qiong 2, LI Hongfei 2   

  1. 1 Department of Neurology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China; 2 Department of Neurology, Dongyang People's Hospital, Dongyang 322100, Zhejiang, China
  • Received:2018-04-25 Revised:2018-06-24 Online:2018-10-26 Published:2018-10-25

摘要:

目的: 研究血管性痴呆(VD)给予法舒地尔联合瑞舒伐他汀治疗对其认知功能、C-反应蛋白及氧化应激的影响。方法: 选取184例VD患者为研究对象,按随机数表法分为瑞舒伐他汀组与联合用药组(法舒地尔+瑞舒伐他汀),各92例。比较两组治疗前后简易精神状态量表(MMSE)、蒙特利尔认知功能量表(MoCA)与日常生活能力量表(ADL)评分、C-反应蛋白(CRP)水平、丙二醛(MDA)、血清同型半胱氨酸(Hcy)与超氧化物歧化酶(SOD)水平、血脂指标(TC、TG、LDL-C、HDL-C)水平、临床疗效及不良反应发生率。结果: 联合用药组治疗总有效率(93.48%)显著高于瑞舒伐他汀组(82.61%),差异有统计学意义(P<0.05);治疗后,联合用药组MMSE、MoCA与ADL量表积分明显高于瑞舒伐他汀组,CRP、MDA、Hcy、TC、TG、LDL-C水平显著低于瑞舒伐他汀组,SOD水平明显高于瑞舒伐他汀组,差异均有统计学意义(P<0.05)。不良反应发生率无统计学意义(P>0.05)。结论: 法舒地尔联合瑞舒伐他汀治疗VD更有利于改善患者认知功能与日常生活能力,降低C-反应蛋白水平与氧化应激反应,改善血脂指标,临床疗效显著,且安全性高。

关键词: 血管性痴呆, 法舒地尔, 瑞舒伐他汀, 认知功能, C-反应蛋白, 氧化应激

Abstract:

AIM: To investigate the effects of fasudil combined with rosuvastatin in the treatment of vascular dementia (VD) on patients' cognitive function, C-reactive protein and oxidative stress.  METHODS: One hundred and eighty-four VD patients were selected as study subjects. They were divided into the rosuvastatin group and the combined drug group (fasudil + rosuvastatin) according to the random number table method. Each group contains 92 cases. MMSE (Mini-Mental State Examination), MoCA (Montreal Cognitive Assessment) and ADL (Activities of Daily Living) scores, the level of CRP (C-reactive protein), MDA (malondialdehyde), Hcy (serum homocysteine) and SOD (superoxide dismutase), as well as blood lipid index (TC, TG, LDL-C, HDL-C) levels, clinical efficacy and incidence of adverse reaction were compared between the two groups before and after treatment. RESULTS:The total effective rate of the combined drug group (93.48%) was significantly higher than that of the rosuvastatin group (82.61%), and the difference was statistically significant (P<0.05). After treatment, the MMSE, MoCA and ADL scores of the combined drug group were significantly higher than that of the rosuvastatin group, while the level of CRP, MDA, Hcy, TC, TG and LDL-C was significantly lower than that of the rosuvastatin group, and the SOD level was significantly higher than that of the rosuvastatin group, which were of statistically significant difference (P<0.05). There was no significant difference in the incidence of adverse reaction (P>0.05). CONCLUSION: Fasudil combined with rosuvastatin in the treatment of VD can improve patients' cognitive function and daily living ability, reduce oxidative stress response and the level of C-reactive protein, and improve patients' blood lipid index. This method is of significant clinical efficacy and high safety.

Key words: vascular dementia, fasudil, rosuvastatin, cognitive function, C-reactive protein, oxidative stress

中图分类号: